Zai Lab (NASDAQ:ZLAB) Releases Earnings Results, Beats Expectations By $0.18 EPS

Zai Lab (NASDAQ:ZLAB) released its earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18, Zacks reports. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%. The business had revenue of $108.21 million for the quarter, compared to the consensus estimate of $107.90 million.

Here are the key takeaways from Zai Lab’s conference call:

• Zoci’s early first-line small cell lung cancer data were encouraging: In 33 evaluable patients, zoci plus atezolizumab produced an 81.8% confirmed response rate and estimated six-month progression-free survival of 81.9%, with grade 3 or higher zoci-related adverse events in 9.1%. The results are from a small early-stage study; Zai Lab plans a global phase III trial and is targeting a potential U.S. BLA submission in 2027.
• Zai Lab expects three registrational studies to be underway by year-end and anticipates two registrational readouts in 2027. For zoci, a potential accelerated-approval filing in second-line or later small cell lung cancer depends on the DLLEVATE interim analysis, while an epNEC filing would depend on forthcoming data and durability follow-up.
• China product revenue increased 2% sequentially, and the commercial business remained profitable. Management expects a return to year-over-year product revenue growth in 2027, citing potential NRDL access expansion and demand across priority brands; that outlook remains a company forecast.
• Zai Lab reported $659.7 million in cash at quarter-end and raised approximately $250 million in October. Management said stable R&D and SG&A expenses, operational efficiencies, and the financing support investment in its global pipeline.
• The company plans to present the first human data for its internally developed atopic dermatitis candidate ZL-1503 next week, with patient efficacy data and an IV-to-subcutaneous bridging study expected in 2027. Zai Lab is also advancing additional oncology and immunology assets, though these programs remain at earlier development stages.

Zai Lab Stock Down 0.9%

Shares of ZLAB stock traded down $0.20 on Thursday, reaching $22.60. The stock had a trading volume of 813,969 shares, compared to its average volume of 885,390. The firm’s 50-day moving average is $24.71 and its two-hundred day moving average is $21.00. The firm has a market capitalization of $2.57 billion, a price-to-earnings ratio of -13.22 and a beta of 0.77. Zai Lab has a 12 month low of $15.96 and a 12 month high of $27.50.

Insider Buying and Selling

In other Zai Lab news, Director William Lis sold 8,506 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total transaction of $212,650.00. Following the transaction, the director owned 41,931 shares of the company’s stock, valued at $1,048,275. The trade was a 16.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 9,385 shares of company stock worth $235,145 in the last three months. Company insiders own 4.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ZLAB. Wall Street Zen upgraded Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a research note on Tuesday, October 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a report on Tuesday, October 27th. Finally, Citigroup increased their price objective on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Zai Lab has a consensus rating of “Moderate Buy” and a consensus target price of $37.25.

Zai Lab News Summary

Here are the key news stories impacting Zai Lab this week:

• Positive Sentiment: Zai Lab reported a Q3 loss of $0.41 per ADS, narrower than the roughly $0.58–$0.59 loss analysts expected. Revenue of $108.21 million also slightly exceeded the $107.90 million consensus. Earnings Flash
• Positive Sentiment: The company highlighted progress toward bringing its first internally developed medicines to patients globally; coverage also pointed to the pipeline’s potential first U.S. drug filing as a future catalyst. Company results and updates Pipeline report
• Negative Sentiment: Some coverage characterized the quarter as having a wider loss and lower revenue versus the year-ago period. Continued losses and revenue pressure could weigh on sentiment despite the beat against analyst estimates. Quarterly results coverage

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.